Posted inNew Drugs, Rare/Orphan Diseases, Regulatory Vijoice: First Targeted Treatment for PIK3CA-Related Overgrowth Spectrum (PROS) April 23, 2022September 8, 2022 Novartis and its alpelisib will help with very rare diseases with malformations and excessive tissue growth.
